Security Snapshot

FILANA THERAPEUTICS, INC. - Common Stock (FLNA) Institutional Ownership

CUSIP: 14817C107

13F Institutional Holders and Ownership History from Q1 2019 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

29

Shares (Excl. Options)

5.32MFull value: 5,315,669 · shares · 30 Sep 2026

Price

$0.89

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / Common Stock
Symbol
FLNA on Nasdaq
All holders as of 30 Sep 2026
Q3 2026
Total 13F shares
5,315,669
Latest holder snapshot 5 signals
Total 13F value
$4,714,570
Portfolio coverage rank
0%
Share change
-789,152
Value change
-$760,757
Number of holders
29
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
48,331,225
SEC-reported price per share
$0.81
Insider filing price
$0.81
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • FLNA - FILANA THERAPEUTICS, INC. - Common Stock is tracked under CUSIP 14817C107.
  • 29 institutions reported positions in Q3 2026.
  • 3 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 82 to 29 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $15.09MFull value: $15,087,441 · USD · 30 Jun 2026
    to
    $4.71MFull value: $4,714,570 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 29 institutions filings for Q3 2026.

Open SEC evidence

Security key

14817C107

13F reference period

Q3 2026

13F holders

29

13D/G owners

3

CIK / CUSIP context first

Open Q3 2026 holders FLNA full holder history FILANA THERAPEUTICS, INC. SEC filings FILANA THERAPEUTICS, INC. company facts FILANA THERAPEUTICS, INC. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
3
Security
FLNA
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Nachtrab Matthew 4.7% $3,560,189 2,267,636 Nachtrab Matthew 16 Aug 2024
VANGUARD GROUP INC 4.5% $3,927,830 2,170,072 The Vanguard Group 30 Jun 2025
BlackRock, Inc. 3.2% $2,797,129 1,545,375 BlackRock, Inc. 30 Jun 2025
As of 30 Sep 2026, 29 institutional investors reported holding
5.32MFull value: 5,315,669 · shares · 30 Sep 2026
shares of FILANA THERAPEUTICS, INC. - Common Stock (FLNA). This represents 11% of the company’s total
48.33MFull value: 48,331,225 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
11%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD CAPITAL MANAGEMENT LLC 4% 1,929,726 -2.3% 0% $1,709,737
MARSHALL WACE, LLP 2.4% 1,161,405 -27% 0% $1,033,652
GEODE CAPITAL MANAGEMENT, LLC 1.3% 612,195 -0.54% 0% $542,615
VANGUARD FIDUCIARY TRUST CO 0.65% 315,889 0% 0% $279,878
RENAISSANCE TECHNOLOGIES LLC 0.46% 222,359 -43% 0% $197,010
STATE STREET CORP 0.43% 209,105 0% 0% $185,267
STIFEL FINANCIAL CORP 0.41% 200,000 +167% 0% $177,200
GROUP ONE TRADING LLC 0.41% 197,160 -19% 0.01% $174,684
VANGUARD PORTFOLIO MANAGEMENT LLC 0.28% 134,337 +1.3% 0% $119,023
FEDERATED HERMES, INC. 0.27% 131,234 +9.4% 0% $116,273
Verition Fund Management LLC 0.1% 46,870 0% 0% $41,527
LPL Financial LLC 0.08% 39,643 -1.3% 0% $35,123
MGO ONE SEVEN LLC 0.07% 33,339 0% 0% $29,538
Apollon Wealth Management, LLC 0.03% 16,414 -13% 0% $14,543
Vanguard Global Advisers, LLC 0.03% 15,897 0% 0% $14,085
Cetera Investment Advisers 0.03% 15,242 0% 0% $13,504
MAYPORT, LLC 0.03% 13,400 0% 0% $11,872
MORGAN STANLEY 0.02% 9,361 -31% 0% $8,294
Activest Wealth Management 0.01% 4,001 0% 0% $3,545
SBI Securities Co., Ltd. 0.01% 2,986 +58% 0% $2,646
Signature Equity Partners, LLC 0% 2,000 0% 0% $1,772
NewEdge Advisors, LLC 0% 1,550 -95% 0% $1,373
Physician Wealth Advisors, Inc. 0% 581 0% $515
TD Waterhouse Canada Inc. 0% 400 0% 0% $384
MATHER GROUP, LLC. 0% 250 0% 0% $222

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
31
Headline period
Q3 2026
Rows shown
1-25 of 31
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 5,315,669 $4,714,570 -$760,757 $0.89 29
2026 Q2 12,678,226 $15,087,441 -$1,525,558 $1.19 82
2026 Q1 13,646,372 $23,061,084 -$584,591 $1.69 99
2025 Q4 13,806,828 $27,336,180 -$753,360 $1.98 105
2025 Q3 13,778,326 $40,074,441 +$5,040,034 $2.91 101
2025 Q2 12,246,863 $22,166,624 -$6,209,960 $1.81 96
2025 Q1 15,768,881 $23,653,533 -$3,650,996 $1.50 114
2024 Q4 17,411,806 $41,096,950 -$26,811,358 $2.36 135
2024 Q3 14,006,298 $412,343,524 +$21,408,686 $29.43 159
2024 Q2 13,297,542 $164,180,761 +$20,340,671 $12.35 140
2024 Q1 11,593,879 $235,338,414 -$49,008,344 $20.29 141
2023 Q4 13,929,974 $313,474,831 +$20,318,834 $22.51 150
2023 Q3 12,909,705 $214,797,641 +$17,325,070 $16.64 136
2023 Q2 11,697,131 $286,735,353 -$6,324,947 $24.52 150
2023 Q1 11,914,630 $287,373,528 +$15,058,161 $24.12 140
2022 Q4 11,254,249 $332,457,243 +$2,217,261 $29.54 146
2022 Q3 10,511,058 $439,522,416 +$28,422,554 $41.82 164
2022 Q2 9,860,019 $277,264,167 -$22,312,348 $28.12 136
2022 Q1 10,487,576 $389,768,314 -$39,764,775 $37.14 147
2021 Q4 11,534,283 $504,052,860 -$49,487,683 $43.70 160
2021 Q3 12,113,852 $751,991,955 +$67,636,793 $62.08 169
2021 Q2 10,434,065 $891,498,117 +$48,315,268 $85.44 163
2021 Q1 10,158,803 $456,594,941 +$91,884,258 $44.95 116
2020 Q4 9,404,804 $64,135,775 +$15,501,397 $6.82 70
2020 Q3 6,699,572 $77,113,513 +$9,133,318 $11.51 63
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .